2025 Global Asthma And Copd Drug Market Revenue Opportunities Report
Description
The 2025 Global Asthma And Copd Drug Market Revenue Opportunities Report features 1) market size data for the region or country, 2) annual market growth rates, 3) the market's impact on related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing, 4) Total Addressable Market (TOM) for the four largest market players, 5) Serviceable Addressable Market (SAM), and 6) Serviceable Obtainable Market (SOM)(Wharry Sharpe Research)
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Asthma and COPD Drug Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the global Asthma and COPD drug market are GlaxoSmithKline (GSK), AstraZeneca, Boehringer Ingelheim, and Novartis. GSK is a leader with innovative biological treatments like depemokimab targeting severe asthma and holds significant respiratory drug revenues through its Ellipta platform, generating nearly GBP 1.6 billion quarterly from respiratory medicines. AstraZeneca complements its portfolio through acquisitions such as Almirall’s respiratory assets and invests in novel biologics and digital-health inhaler solutions, enhancing asthma and COPD care. Boehringer Ingelheim and Novartis maintain strong positions with extensive inhaler product lines and pipeline expansions targeting inflammation pathways to address COPD and asthma effectively.
These companies shape the market with strong R&D focus on long-acting anti-inflammatory therapies, monoclonal antibodies, and improved drug delivery systems for inhaled medications, which dominate 73.1% of drug administration routes. Their investments respond to rising global asthma and COPD prevalence fueled by urban pollution and increased tobacco use, driving demand for effective, convenient therapies with fewer side effects. Ongoing innovations like combination drugs and longer-duration biologics aim to improve patient outcomes worldwide, supported by expanding healthcare infrastructure and regulatory frameworks.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Asthma and COPD Drug Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the global Asthma and COPD drug market are GlaxoSmithKline (GSK), AstraZeneca, Boehringer Ingelheim, and Novartis. GSK is a leader with innovative biological treatments like depemokimab targeting severe asthma and holds significant respiratory drug revenues through its Ellipta platform, generating nearly GBP 1.6 billion quarterly from respiratory medicines. AstraZeneca complements its portfolio through acquisitions such as Almirall’s respiratory assets and invests in novel biologics and digital-health inhaler solutions, enhancing asthma and COPD care. Boehringer Ingelheim and Novartis maintain strong positions with extensive inhaler product lines and pipeline expansions targeting inflammation pathways to address COPD and asthma effectively.
These companies shape the market with strong R&D focus on long-acting anti-inflammatory therapies, monoclonal antibodies, and improved drug delivery systems for inhaled medications, which dominate 73.1% of drug administration routes. Their investments respond to rising global asthma and COPD prevalence fueled by urban pollution and increased tobacco use, driving demand for effective, convenient therapies with fewer side effects. Ongoing innovations like combination drugs and longer-duration biologics aim to improve patient outcomes worldwide, supported by expanding healthcare infrastructure and regulatory frameworks.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
Table of Contents
51 Pages
- A. Definitions
- A1. Market Definition
- A2. Market Segmentation
- A3. Industry Opportunities-Industry1
- A4. Industry Opportunities-Industry2
- A5. Industry Opportunities-Industry3
- B. Total Addressable Market (TAM)
- B1. TAM-Player 1/4
- B2. TAM-Player 2/4
- B3. TAM-Player 3/4
- B4. TAM-Player 4/4
- C. Serviceable Addressable Market (SAM)
- C1. SAM-Player 1/4
- C2. SAM-Player 2/4
- C3. SAM-Player 3/4
- C4. SAM-Player 4/4
- D. Serviceable Obtainable Market (SOM)
- D1. SOM-Player 1/4
- D2. SOM-Player 2/4
- D3. SOM-Player 3/4
- D4. SOM-Player 4/4
- E. Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
